Rebecca Lauren Tisdale

Rebecca Lauren Tisdale

Auto-generated profile, based on publicly available information

Rebecca Lauren Tisdale

Medical Service, VA Palo Alto Healthcare System, CA (R.L.T., N.M.K., A.V., N.D., A.S., P.H.).

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MCMarika M. Cusick
Marika M. Cusick
RTRebecca L. Tisdale
Rebecca L. Tisdale
GCGlenn M. Chertow
Glenn M. Chertow
DODouglas K. Owens
Douglas K. Owens
JGJeremy D. Goldhaber-Fiebert
Jeremy D. Goldhaber-Fiebert
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have the potential to alter the natural history of chronic kidney disease (CKD), and they should be included in cost-effectiveness analyses of screening for CKD. To determine the cost-effectiveness of adding population-wide screening for CKD. Markov cohort model. NHANES (National Health and Nutrition Examination Survey), U.S. Centers for Medicare & Medicaid Services data, cohort studies, and randomized clinical trials, including the DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial. Adults. Lifetime. Health care sector. Screening for albuminuria with and without adding SGLT2 inhibitors to the current standard of care for CKD. Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs), all discounted at 3% annually. One-time CKD screening at age 55 years had an ICER of $86 300 per QALY gained by increasing costs from $249 800 to $259 000 and increasing QALYs from 12.61 to 12.72; this was accompanied by a decrease in the incidence of kidney failure requiring dialysis or kidney transplant of 0.29 percentage points and an increase in life expectancy from 17.29 to 17.45 years. Other options were also cost-effective. During ages 35 to 75 years, screening once prevented dialysis or transplant in 398 000 people and screening every 10 years until age 75 years cost less than $100 000 per QALY gained. When SGLT2 inhibitors were 30% less effective, screening every 10 years during ages 35 to 75 years cost between $145 400 and $182 600 per QALY gained, and price reductions would be required for screening to be cost-effective. The efficacy of SGLT2 inhibitors was derived from a single randomized controlled trial. Screening adults for albuminuria to identify CKD could be cost-effective in the United States. Agency for Healthcare Research and Quality, Veterans Affairs Office of Academic Affiliations, and National Institute of Diabetes and Digestive and Kidney Diseases.

1 November 2022 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
JZJimmy Zheng
Jimmy Zheng
RTRebecca L. Tisdale
Rebecca L. Tisdale
PHPaul Heidenreich
Paul Heidenreich
ASAlexander T. Sandhu
Alexander T. Sandhu
Background: Reducing hospital length of stay (LOS) has been identified as an important lever for minimizing the burden of heart failure hospitalization, yet the impact of social and structural determinants of health on LOS has received little attention. We investigated disparities in LOS across race/ethnicity and their possible drivers. Methods: We analyzed patients hospitalized for heart failure from 2017 to 2020 using the Get With The Guidelines-Heart Failure registry. We characterized LOS differences across race/ethnicity by insurance and disposition, adjusting for demographics, comorbidities, and clinical severity. Effects of hospital-level clustering on LOS across race/ethnicity were assessed using hierarchical mixed-effects models. We evaluated the association between LOS and discharge rates of guideline-directed medical therapy. Results: Three thousand three seven hundred thirty patients hospitalized for heart failure were identified. After excluding inpatient deaths, the adjusted LOS for Black (5.72 days [95% CI, 5.62–5.82]), Hispanic (5.94 days [95% CI, 5.79–6.08]), and Indigenous American/Pacific Islander (6.06 days [95% CI, 5.85–6.27]) patients remained significantly longer compared with non-Hispanic White patients (5.32 days [95% CI, 5.25–5.39]). This pattern was driven by LOS differences among patients discharged to hospice or nursing facilities. After accounting for variability between hospitals, associations of race/ethnicity with LOS either were attenuated or reversed in direction. Guideline-directed medical therapy rates on discharge did not differ significantly across race/ethnicity despite longer LOS for Black, Hispanic, and Indigenous American/Pacific Islander patients. Conclusions: Differences between hospitals drive LOS disparities across race/ethnicity. Longer LOS among Black, Hispanic, and Indigenous American/Pacific Islander patients was not associated with improved quality of care.

8 February 2022 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
RTRebecca L. Tisdale
Rebecca L. Tisdale
MCMarika M. Cusick
Marika M. Cusick
KAKelly Zhang Aluri
Kelly Zhang Aluri
THThomas J. Handley
Thomas J. Handley
AJAlice Kate Cummings Joyner
Alice Kate Cummings Joyner
DODouglas K. Owens
Douglas K. Owens

9 November 2022 in JACC: Heart Failure
Verified
Journal Article
Closed access
CWCeleste Witting
Celeste Witting
JZJimmy Zheng
Jimmy Zheng
RTRebecca L. Tisdale
Rebecca L. Tisdale
ESEvan Shannon
Evan Shannon
SKShun Kohsaka
Shun Kohsaka
ASAlexander Sandhu
Alexander Sandhu

19 July 2022 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
PGPascal Geldsetzer
Pascal Geldsetzer
SFSergio Flores
Sergio Flores
GWGrace Wang
Grace Wang
BFBlanca Flores
Blanca Flores
ARAbu Bakarr Rogers
Abu Bakarr Rogers
RTRebecca Tisdale
Rebecca Tisdale
Mobile health (mHealth) interventions hold promise for addressing the epidemic of noncommunicable diseases (NCDs) in low- and middle-income countries (LMICs) by assisting healthcare providers managing these disorders in low-resource settings. We aimed to systematically identify and assess provider-facing mHealth applications used to screen for, diagnose, or monitor NCDs in LMICs. In this systematic review, we searched the indexing databases of PubMed, Web of Science, and Cochrane Central for studies published between January 2007 and October 2019. We included studies of technologies that were: (i) mobile phone- or tablet-based, (ii) able to screen for, diagnose, or monitor an NCD of public health importance in LMICs, and (iii) targeting health professionals as users. We extracted disease type, intervention purpose, target population, study population, sample size, study methodology, technology stage, country of development, operating system, and cost. Our initial search retrieved 13,262 studies, 315 of which met inclusion criteria and were analyzed. Cardiology was the most common clinical domain of the technologies evaluated, with 89 publications. mHealth innovations were predominantly developed using Apple’s iOS operating system. Cost data were provided in only 50 studies, but most technologies for which this information was available cost less than 20 USD. Only 24 innovations targeted the ten NCDs responsible for the greatest number of disability-adjusted life years lost globally. Most publications evaluated products created in high-income countries. Reported mHealth technologies are well-developed, but their implementation in LMICs faces operating system incompatibility and a relative neglect of NCDs causing the greatest disease burden.

24 August 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CGCaroline Gray
Caroline Gray
CWCharlie Wray
Charlie Wray
RTRebecca Tisdale
Rebecca Tisdale
CCCamila Chaudary
Camila Chaudary
CSCindie Slightam
Cindie Slightam
DZDonna Zulman
Donna Zulman
Background: The rapid implementation of virtual care (ie, telephone or video-based clinic appointments) during the COVID-19 pandemic resulted in many providers offering virtual care with little or no formal training and without clinical guidelines and tools to assist with decision-making. As new guidelines for virtual care provision take shape, it is critical that they are informed by an in-depth understanding of how providers make decisions about virtual care in their clinical practices. Objective: In this paper, we sought to identify the most salient factors that influence how providers decide when to offer patients video appointments instead of or in conjunction with in-person care. Methods: We conducted semistructured interviews with 28 purposefully selected primary and specialty health care providers from the US Department of Veteran’s Affairs health care system. We used an inductive approach to identify factors that impact provider decision-making. Results: Qualitative analysis revealed distinct clinical, patient, and provider factors that influence provider decisions to initiate or continue with virtual visits. Clinical factors include patient acuity, the need for additional tests or labs, changes in patients’ health status, and whether the patient is new or has no recent visit. Patient factors include patients’ ability to articulate symptoms or needs, availability and accessibility of technology, preferences for or against virtual visits, and access to caregiver assistance. Provider factors include provider comfort with and acceptance of virtual technology as well as virtual physical exam skills and training. Conclusions: Providers within the US Department of Veterans Affairs health administration system consider a complex set of factors when deciding whether to offer or continue a video or telephone visit. These factors can inform the development and further refinement of decision tools, guides, and other policies to ensure that virtual care expands access to high-quality care.